ftInvstr
MOREPENLAB · Healthcare ₹113.6 -3.15% Mkt Cap ₹6185 Cr

MOREPENLAB

Healthcare Drug Manufacturers - Specialty & Generic
₹113.6
-3.15% today · 30d +42.8%
as of 2026-09-04
Price · Daily Candles
“Morepen Labs surges as Q1 profit rockets +424.73% YoY; FIIs trim holdings.”
Morepen Laboratories recorded a strong Q1 2026 performance with net profit soaring +424.73% YoY to ₹56 Cr and revenue increasing +34.07% YoY to ₹570 Cr. Despite this, the stock trades at a TTM P/E of 44.48, significantly higher than some peers, and is currently free-cash-flow negative at -₹53 Cr.
BULL CASE
+Q1 2026 net profit surged +424.73% YoY to ₹56 Cr, driven by strong revenue growth.
+Quarterly revenue for Q1 2026 jumped +34.07% YoY to ₹570 Cr, indicating robust operational performance.
+The stock has delivered strong short-term returns, with a +76.16% gain in the last 3 months and +111.24% over 6 months.
+Operating profit for Q1 2026 saw a substantial increase of +206.93% YoY to ₹88 Cr.
BEAR CASE
Despite strong quarterly growth, annual net profit for FY26 decreased by -19.61% YoY to ₹95 Cr.
The company's TTM P/E of 44.48 is higher than sector peers like ZYDUSLIFE (21.85) and LUPIN (20.43).
Morepen Labs is currently free-cash-flow negative at -₹53 Cr, resulting in a FCF yield of -1.27%.
FIIs reduced their stake by -0.12% QoQ in Q1 2026, while DII holdings saw a marginal increase of +0.03%.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹570 Cr
+34.07% YoY
NET PROFIT
₹56 Cr
+424.73% YoY
OPM
15.25%
+8.6pp YoY
EPS
₹1.03
PE 44.48
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-0.9% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Morepen Labs' TTM P/E of 44.48 is higher than peers like ZYDUSLIFE (21.85) and LUPIN (20.43), while its ROCE of 15.0% trails behind SUNPHARMA (21.44%) and DIVISLAB (21.56%).
PEERPEROCE %
MOREPENLAB44.4815.0
SUNPHARMA38.4121.44
DIVISLAB82.0221.56
CIPLA35.1218.37
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
65
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 100
Valuation FAIR 40
Growth DECLINING 26
Profitability HIGH 78
Technicals NEUTRAL 68
Risk LOW 80
Key Stats
TTM PE
44.48
P/B
3.47
52W HIGH
₹118.55
OFF HIGH
-4.18%
DIV YIELD
0.29%
MKT CAP
₹6185 Cr
◉ Active Signals
MACDBullish1.2929
RSI(14)Bearish74.85
Near 52W HighBullish-4.18
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold MOREPENLAB and at what entry.

Sign up freeSign in